Antibody avidity and immunoglobulin G isotype distribution following immunization with a monovalent meningococcal B outer membrane vesicle vaccine.
about
Mucosal targeting of a BoNT/A subunit vaccine adjuvanted with a mast cell activator enhances induction of BoNT/A neutralizing antibodies in rabbitsTailoring subunit vaccine immunity with adjuvant combinations and delivery routes using the Middle East respiratory coronavirus (MERS-CoV) receptor-binding domain as an antigen.Preclinical studies of human immunodeficiency virus/AIDS vaccines: inverse correlation between avidity of anti-Env antibodies and peak postchallenge viremia.Pre-clinical evaluation of a novel nanoemulsion-based hepatitis B mucosal vaccineSoluble HIV-1 Env trimers in adjuvant elicit potent and diverse functional B cell responses in primates.Characterization of antibodies induced by vaccination with hepatitis C virus envelope glycoproteins.Lack of avidity maturation of merozoite antigen-specific antibodies with increasing exposure to Plasmodium falciparum amongst children and adults exposed to endemic malaria in Kenya.Avidity of anti-circumsporozoite antibodies following vaccination with RTS,S/AS01E in young children.Mucosal vaccination against serogroup B meningococci: induction of bactericidal antibodies and cellular immunity following intranasal immunization with NadA of Neisseria meningitidis and mutants of Escherichia coli heat-labile enterotoxin.Incorporation of a GPI-anchored engineered cytokine as a molecular adjuvant enhances the immunogenicity of HIV VLPs.Development and application of a GuHCl-modified ELISA to measure the avidity of anti-HPV L1 VLP antibodies in vaccinated individualsPreexisting vaccinia virus immunity decreases SIV-specific cellular immunity but does not diminish humoral immunity and efficacy of a DNA/MVA vaccinePersistent Low-Level Replication of SIVΔnef Drives Maturation of Antibody and CD8 T Cell Responses to Induce Protective Immunity against Vaginal SIV InfectionCharacteristics of RSV-Specific Maternal Antibodies in Plasma of Hospitalized, Acute RSV Patients under Three Months of AgeGM-CSF DNA: an adjuvant for higher avidity IgG, rectal IgA, and increased protection against the acute phase of a SHIV-89.6P challenge by a DNA/MVA immunodeficiency virus vaccine.Evaluation of the immune responses induced by four targeted DNA vaccines encoding the juvenile liver fluke antigen, cathepsin B in a mouse model.Hyperproliferation of B cells specific for a weakly immunogenic PorA in a meningococcal vaccine model.Neisseria lactamica antigens complexed with a novel cationic adjuvantLiposomal meningococcal B vaccination: role of dendritic cell targeting in the development of a protective immune response.An HIV-1 Env-Antibody Complex Focuses Antibody Responses to Conserved Neutralizing Epitopes.High Doses of GM-CSF Inhibit Antibody Responses in Rectal Secretions and Diminish Modified Vaccinia Ankara/Simian Immunodeficiency Virus Vaccine Protection in TRIM5α-Restrictive Macaques.Mucosal immunization of mice with recombinant OMP P2 induces antibodies that bind to surface epitopes of multiple strains of nontypeable Haemophilus influenzae.Understanding the immune responses to the meningococcal strain-specific vaccine MeNZB measured in studies of infants.Avidity of IgG antibodies against meningococcal serogroup a polysaccharide and correlations with bactericidal activity in sera from meningitis patients and controls from Ethiopia.Avidity progression of dietary antibodies in healthy and coeliac children.Bioengineered polyester beads co-displaying protein and carbohydrate-based antigens induce protective immunity against bacterial infection.Factors influencing the induction of high affinity antibodies to Plasmodium falciparum merozoite antigens and how affinity changes over time.
P2860
Q28476839-CFBFB82A-EE64-4075-87E1-5F2D3C2DBA6BQ30368736-AEAF5696-7456-46D5-8D75-54AA5034E3E3Q30374995-6AC1F4D0-8A3E-4544-A7B6-A9445A22F1B7Q33359620-4DD713FA-CA65-42C8-86B9-2E64062AFF57Q34096530-E2485584-7B3E-4302-B81A-7A6C3DCE81A9Q34097560-099491CA-98F1-4E69-8EB2-348B97F3AB76Q34541443-1D603948-B4E3-4262-B19C-9380A2BF5CCBQ34704130-95C0F40D-ACA0-4F8D-AC7A-BD0FD9B02784Q34761746-BF6C07E4-B4D3-4F5A-A407-4940C6FE23E5Q35824686-32AFF7A4-782F-423A-BB80-FF6AE534DD37Q35869579-44E74845-D458-4284-8FE6-C6E5D4CBB3DCQ36141586-91F6AD74-A9DD-4A62-AB21-503414CA5ACDQ36222317-7CD2EAE6-0655-4868-AC22-C4319DF3E107Q36263882-AC7C6D4F-3577-4D07-A351-FDC9AAE1F834Q36407775-17F986B0-1EAB-4136-8794-B35157B6987EQ36419849-AD4B5261-D81F-43C2-B737-A81B32EE96DFQ36933060-F4B102CF-C1F5-41CC-83C9-59D0E62DC4EDQ37478314-0FCD6997-DAF3-4BEB-9D39-A2FDC9D7898EQ39863852-EA884E77-06A1-4E8E-98EF-08371BEA5715Q40463159-D01D6D49-66DE-4CDF-88FF-A458F143D6D1Q40523370-023BB4D9-C283-427E-927F-1F19C7AAEF07Q41171683-E9EFDB85-CA98-4CA0-91AF-278C7CFFC854Q41479856-F73ABF8B-20C4-4988-9C12-8C7FAB35370EQ42234518-3CFA1F7C-E497-4E9D-9CF7-90B01F0DB53BQ47385703-65B33873-DAC3-459D-8306-CF22F4308769Q48138824-7EBEABF6-0A93-4FBA-AE5D-8EC107FE6C1DQ55248535-84A97764-5F8B-448D-A0EC-B96D0FCE68DE
P2860
Antibody avidity and immunoglobulin G isotype distribution following immunization with a monovalent meningococcal B outer membrane vesicle vaccine.
description
2002 nî lūn-bûn
@nan
2002 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Antibody avidity and immunoglo ...... uter membrane vesicle vaccine.
@ast
Antibody avidity and immunoglo ...... uter membrane vesicle vaccine.
@en
Antibody avidity and immunoglo ...... uter membrane vesicle vaccine.
@nl
type
label
Antibody avidity and immunoglo ...... uter membrane vesicle vaccine.
@ast
Antibody avidity and immunoglo ...... uter membrane vesicle vaccine.
@en
Antibody avidity and immunoglo ...... uter membrane vesicle vaccine.
@nl
prefLabel
Antibody avidity and immunoglo ...... uter membrane vesicle vaccine.
@ast
Antibody avidity and immunoglo ...... uter membrane vesicle vaccine.
@en
Antibody avidity and immunoglo ...... uter membrane vesicle vaccine.
@nl
P2093
P2860
P1476
Antibody avidity and immunoglo ...... uter membrane vesicle vaccine.
@en
P2093
C J P van Limpt
C L Vermont
G P J M van Den Dobbelsteen
H H van Dijken
L van Alphen
R de Groot
P2860
P304
P356
10.1128/IAI.70.2.584-590.2002
P407
P577
2002-02-01T00:00:00Z